Tozinameran: Myocarditis and pericarditis.

In a retrospective and observational study of 681 patients, two women developed myocarditis or pericarditis after receiving the tozinameran vaccine for COVID-19. The exact ages of the women were not provided, and details about the routes, dosages, and timing of the reactions were also not stated. One patient developed myocarditis, while the other developed pericarditis as a result of the tozinameran vaccine. [Extracted from the article]